Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Two Mega-Mergers Were Just The Highlights Of A Year Of Major Deals

Jan 15 2020

• By Joseph Haas

Scrip Perspectives 2019 to 2020 — 2019 saw two biopharma mega-mergers and 23 deals with upfront value of $1bn or more

Related Content

Celgene's Otezla Sale Shows FTC Wants Merging Companies To Ditch Marketed, Not Pipeline, Products

Aug 30 2019

Takeda Offloads Xiidra As Expected, For $3.4bn Upfront To Novartis

May 09 2019

Related Companies

AstraZeneca PLC

Daiichi Sankyo Co., Ltd.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

AbbVie Inc.

Allergan plc

Takeda Pharmaceutical Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Amgen, Inc.

Novartis AG

Pfizer Inc.

Array BioPharma, Inc.

Nestle Health Science

Galderma S.A.

The Medicines Company

Eli Lilly and Company

Loxo Oncology at Lilly

Roche Holding AG

Spark Therapeutics, Inc.

Astellas Pharma, Inc.

Astellas Gene Therapies

Additional Topics

Deals M & A Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window